Global Nasal Spray Live Attenuated Influenza Vaccine Market Growth 2025-2031

The global Nasal Spray Live Attenuated Influenza Vaccine market size is predicted to grow from US$ 841 million in 2025 to US$ 1266 million in 2031; it is expected to grow at a CAGR of 7.1% from 2025 to 2031.

Nasal Spray Live Attenuated Influenza Vaccine (LAIV), often marketed under the brand name FluMist, is a type of influenza vaccine designed to protect against the influenza virus. Unlike traditional injectable influenza vaccines, which contain inactivated (killed) virus particles, LAIV contains a weakened, live influenza virus. This live virus is attenuated, meaning it has been modified to reduce its virulence (ability to cause disease) while still retaining the capacity to stimulate an immune response.

Fluctuating Usage: The use of LAIV has seen fluctuations in recent years. In the United States, for example, there was a period when the Advisory Committee on Immunization Practices (ACIP) recommended against the use of LAIV due to concerns about its effectiveness against certain influenza strains. Subsequently, ACIP reinstated its recommendation for LAIV, but these fluctuations have had an impact on the market.

Pediatric Vaccination: LAIV has been particularly popular for pediatric vaccination. Its non-invasive administration method (nasal spray) has made it a preferred choice for children who may have needle phobias or resistance to traditional injectable vaccines.

Global Market Variation: The availability and popularity of LAIV can vary by country and region. Some countries have embraced LAIV more enthusiastically than others, influenced by factors like regulatory approvals, healthcare policies, and local preferences.

Combination Vaccines: Research is ongoing in developing combination vaccines that may include LAIV alongside other vaccines, such as those for COVID-19. These combination vaccines aim to simplify the vaccination process and increase immunization coverage.

LP Information, Inc. (LPI) ' newest research report, the “Nasal Spray Live Attenuated Influenza Vaccine Industry Forecast” looks at past sales and reviews total world Nasal Spray Live Attenuated Influenza Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Nasal Spray Live Attenuated Influenza Vaccine sales for 2025 through 2031. With Nasal Spray Live Attenuated Influenza Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Nasal Spray Live Attenuated Influenza Vaccine industry.

This Insight Report provides a comprehensive analysis of the global Nasal Spray Live Attenuated Influenza Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Nasal Spray Live Attenuated Influenza Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Nasal Spray Live Attenuated Influenza Vaccine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Nasal Spray Live Attenuated Influenza Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Nasal Spray Live Attenuated Influenza Vaccine.

This report presents a comprehensive overview, market shares, and growth opportunities of Nasal Spray Live Attenuated Influenza Vaccine market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Trivalent Flu Vaccine
Quadrivalent Flu Vaccine

Segmentation by Application:
Hospital
Clinic
Public Health Agency
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Sanofi Pasteur
AstraZeneca
CSL
Abbott
GlaxoSmithKline
Serum Institute
Fluenz Tetra
BioDiem
FluMist
ChangChun High & New Technology
BCHT Biotechnology

Key Questions Addressed in this Report

What is the 10-year outlook for the global Nasal Spray Live Attenuated Influenza Vaccine market?

What factors are driving Nasal Spray Live Attenuated Influenza Vaccine market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Nasal Spray Live Attenuated Influenza Vaccine market opportunities vary by end market size?

How does Nasal Spray Live Attenuated Influenza Vaccine break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.